A new article argues dystrophin immunogenicity is an under-examined issue in the treatment of Duchenne muscular dystrophy.

Definition of Duchenne Muscular Dystrophy (DMD ... Three other diseases that fall into this group are: Becker muscular dystrophy or (BMD), this is a mild form of DMD Intermediate clinical ...

Edgewise Therapeutics, Inc.’s EWTX share price has surged by 7.97%, which has investors questioning if this is right time to sell.

Duchenne muscular dystrophy (DMD ... Three other diseases that fall into this group are: Becker muscular dystrophy or Becker Muscular Dystrophy (BMD), this is a mild form of DMD Intermediate clinical ...

We recently published a list of 20 Stocks Insiders Bought in April After Trump’s Tariff Rollout. In this article, we are going to take a look at where Edgewise Therapeutics, Inc. (NASDAQ:EWTX) stands ...

Its lead drug, EDG-5506, aims to prevent muscle damage in patients with Duchenne and Becker muscular dystrophy. The Boulder, Colorado-based company also develops EDG-7500 for hypertrophic ...

A father will soon take on a half marathon following his five-year-old son’s diagnosis with a muscle-wasting condition, which ...

Its lead drug, EDG-5506, aims to prevent muscle damage in patients with Duchenne and Becker muscular dystrophy. The Boulder, Colorado-based company also develops EDG-7500 for hypertrophic ...

Duchenne muscular dystrophy (DMD) is caused by pathogenic variants in the dystrophin gene. It exhibits an X-linked inheritance pattern, affecting approximately 1 in 3,500 to 5,000 liveborn boys. The ...

Edgewise intends to use the net proceeds from the offering to support the potential U.S. commercial launch of sevasemten in patients with Becker ... in Duchenne muscular dystrophy, Phase 3 trials ...